{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T07:13:41Z","timestamp":1788592421071,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T00:00:00Z","timestamp":1618617600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T00:00:00Z","timestamp":1618617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008018","name":"Mutuelle G\u00e9n\u00e9rale de l'Education Nationale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008017","name":"Institut Gustave-Roussy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008017","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012948","name":"Minist\u00e8re de l'Enseignement sup\u00e9rieur, de la Recherche et de l'Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Menopausal hormone therapy (MHT) is a risk factor for breast cancer (BC). Evidence suggests that its effect on BC risk could be partly mediated by mammographic density. The aim of this study was to investigate the relationship between MHT, mammographic density and BC risk using data from a prospective study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used data from a case-control study nested within the French cohort E3N including 453 cases and 453 matched controls. Measures of mammographic density, history of MHT use during follow-up and information on potential confounders were available for all women. The association between MHT and mammographic density was evaluated by linear regression models. We applied mediation modelling techniques to estimate, under the hypothesis of a causal model, the proportion of the effect of MHT on BC risk mediated by percent mammographic density (PMD) for BC overall and by hormone receptor status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among MHT users, 4.2% used exclusively oestrogen alone compared with 68.3% who used exclusively oestrogens plus progestogens. Mammographic density was higher in current users (for a 60-year-old woman, mean PMD 33%; 95% CI 31 to 35%) than in past (29%; 27 to 31%) and never users (24%; 22 to 26%). No statistically significant association was observed between duration of MHT and mammographic density. In past MHT users, mammographic density was negatively associated with time since last use; values similar to those of never users were observed in women who had stopped MHT at least 8\u2009years earlier. The odds ratio of BC for current versus never MHT users, adjusted for age, year of birth, menopausal status at baseline and BMI, was 1.67 (95% CI, 1.04 to 2.68). The proportion of effect mediated by PMD was 34% for any BC and became 48% when the correlation between BMI and PMD was accounted for. These effects were limited to hormone receptor-positive BC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results suggest that, under a causal model, nearly half of the effect of MHT on hormone receptor-positive BC risk is mediated by mammographic density, which appears to be modified by MHT for up to 8\u2009years after MHT termination.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13058-021-01425-8","type":"journal-article","created":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T09:02:31Z","timestamp":1618650151000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Association between menopausal hormone therapy, mammographic density and breast cancer risk: results from the E3N cohort study"],"prefix":"10.1186","volume":"23","author":[{"given":"M.","family":"Fornili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Perduca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"J\u00e9rolon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C.","family":"Boutron-Ruault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Maskarinec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7157-419X","authenticated-orcid":false,"given":"G.","family":"Severi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Baglietto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,17]]},"reference":[{"key":"1425_CR1","doi-asserted-by":"publisher","unstructured":"Pettersson A, Graff RE, Ursin G, Dos Santos SI, McCormack V, Baglietto L, et al. Mammographic density phenotypes and risk of breast cancer: a meta-analysis. J Natl Cancer Inst. 2014;106(5). https:\/\/doi.org\/10.1093\/jnci\/dju078.","DOI":"10.1093\/jnci\/dju078"},{"issue":"4","key":"1425_CR2","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1158\/1055-9965.EPI-16-0499","volume":"26","author":"K Krishnan","year":"2017","unstructured":"Krishnan K, Baglietto L, Stone J, Simpson JA, Severi G, Evans CF, MacInnis RJ, Giles GG, Apicella C, Hopper JL. Longitudinal study of mammographic density measures that predict breast cancer risk. Cancer Epidemiol Biomark Prev. 2017;26(4):651\u201360. https:\/\/doi.org\/10.1158\/1055-9965.EPI-16-0499.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"9","key":"1425_CR3","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1093\/aje\/kwn063","volume":"167","author":"LE Kelemen","year":"2008","unstructured":"Kelemen LE, Pankratz VS, Sellers TA, Brandt KR, Wang A, Janney C, Fredericksen ZS, Cerhan JR, Vachon CM. Age-specific trends in mammographic density: the Minnesota Breast Cancer Family Study. Am J Epidemiol. 2008;167(9):1027\u201336. https:\/\/doi.org\/10.1093\/aje\/kwn063.","journal-title":"Am J Epidemiol"},{"key":"1425_CR4","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/ijc.25252","volume":"127","author":"VA McCormack","year":"2010","unstructured":"McCormack VA, Perry NM, Vinnicombe SJ, Dos Santos Silva I. Changes and tracking of mammographic density in relation to Pike\u2019s model of breast tissue aging: a UK longitudinal study. Int J Cancer. 2010;127:452\u201361.","journal-title":"Int J Cancer"},{"key":"1425_CR5","doi-asserted-by":"crossref","unstructured":"Cagnacci A, Venier M. The controversial history of hormone replacement therapy. Medicina. 2019;55(9):602.","DOI":"10.3390\/medicina55090602"},{"key":"1425_CR6","unstructured":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. A review of human carcinogens. Part A: Pharmaceuticals. Lyon: IARC Monoghaphs; 2008."},{"key":"1425_CR7","doi-asserted-by":"crossref","unstructured":"Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individualparticipant meta-analysis of the worldwide epidemiological evidence. Lancet; 2019;394:1159\u201368.","DOI":"10.1016\/S0140-6736(19)31709-X"},{"key":"1425_CR8","doi-asserted-by":"crossref","unstructured":"Azam S, Jacobsen KK, Aro AR, Lynge E, Andersen ZJ. Hormone replacement therapy and mammographic density: a systematic literature review. Breast Cancer Res Treat. 2020 [cited 2020 Nov 18]. p. 555\u201379. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32572713\/","DOI":"10.1007\/s10549-020-05744-w"},{"key":"1425_CR9","unstructured":"Azam S, Jacobsen KK, Aro AR, Lynge E, Andersen ZJ. Hormone replacement therapy and mammographic density: a systematic literature review.Breast Cancer Res. Treat. 2020;182:555\u201379."},{"key":"1425_CR10","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13058-016-0750-0","volume":"18","author":"MS Rice","year":"2016","unstructured":"Rice MS, Bertrand KA, VanderWeele TJ, Rosner BA, Liao X, Adami H-O, et al. Mammographic density and breast cancer risk: a mediation analysis. Breast Cancer Res. 2016;18:94.","journal-title":"Breast Cancer Res"},{"key":"1425_CR11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10552-018-1033-0","volume":"29","author":"S Azam","year":"2018","unstructured":"Azam S, Lange T, Huynh S, Aro AR, von Euler-Chelpin M, Vejborg I, et al. Hormone replacement therapy, mammographic density, and breast cancer risk: a cohort study. Cancer Causes Control. 2018;29:495\u2013505 [cited 2020 Dec 2] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29671181\/.","journal-title":"Cancer Causes Control"},{"key":"1425_CR12","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.canep.2017.07.003","volume":"49","author":"G Maskarinec","year":"2017","unstructured":"Maskarinec G, Dartois L, Delaloge S, Hopper J, Clavel-Chapelon F, Baglietto L. Tumor characteristics and family history in relation to mammographic density and breast cancer: the French E3N cohort. Cancer Epidemiol. 2017;49:156\u201360. https:\/\/doi.org\/10.1016\/j.canep.2017.07.003.","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"1425_CR13","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1093\/ije\/dyu184","volume":"44","author":"F Clavel-Chapelon","year":"2015","unstructured":"Clavel-Chapelon F. Cohort profile: the French E3N cohort study. Int J Epidemiol. 2015;44(3):801\u20139. https:\/\/doi.org\/10.1093\/ije\/dyu184.","journal-title":"Int J Epidemiol"},{"key":"1425_CR14","unstructured":"Yaffe MJ. Breast cancer risk and measured mammographic density. Eur J Cancer Prev. Eur J Cancer Prev; 1998 [cited 2020 Nov 26];7. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/10866036\/"},{"issue":"2","key":"1425_CR15","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/bjc.1995.358","volume":"72","author":"NF Boyd","year":"1995","unstructured":"Boyd NF, Fishell E, Jong R, MacDonald JC, Sparrow RK, Simor IS, Kriukov V, Lockwood G, Tritchler D. Mammographic densities as a criterion for entry to a clinical trial of breast cancer prevention. Br J Cancer. 1995;72(2):476\u20139. https:\/\/doi.org\/10.1038\/bjc.1995.358.","journal-title":"Br J Cancer"},{"issue":"8","key":"1425_CR16","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1200\/JCO.2007.13.4338","volume":"26","author":"A Fournier","year":"2008","unstructured":"Fournier A, Fabre A, Mesrine S, Boutron-Ruault M-C, Berrino F, Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol. 2008;26(8):1260\u20138. https:\/\/doi.org\/10.1200\/JCO.2007.13.4338.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1425_CR17","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1093\/aje\/kwq332","volume":"172","author":"TJ Vanderweele","year":"2010","unstructured":"Vanderweele TJ, Vansteelandt S. Odds ratios for mediation analysis for a dichotomous outcome. Am J Epidemiol. 2010;172(12):1339\u201348. https:\/\/doi.org\/10.1093\/aje\/kwq332.","journal-title":"Am J Epidemiol"},{"key":"1425_CR18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/sim.4780110204","volume":"11","author":"LS Freedman","year":"1992","unstructured":"Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Stat Med. 1992;11:167\u201378 [cited 2021 Mar 4] Available from: http:\/\/doi.wiley.com\/10.1002\/sim.4780110204.","journal-title":"Stat Med"},{"issue":"4","key":"1425_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1037\/a0020761","volume":"15","author":"K Imai","year":"2010","unstructured":"Imai K, Keele L, Tingley D. A general approach to causal mediation analysis. Psychol Methods. 2010;15(4):309\u201334. https:\/\/doi.org\/10.1037\/a0020761.","journal-title":"Psychol Methods"},{"key":"1425_CR20","doi-asserted-by":"crossref","unstructured":"J\u00e9rolon A, Baglietto L, Birmel\u00e9 E, Alarcon F, Perduca V. Causal mediation analysis in presence of multiple mediators uncausally related. Int J Biostat. De Gruyter Open Ltd; 2020;","DOI":"10.1515\/ijb-2019-0088"},{"key":"1425_CR21","doi-asserted-by":"crossref","unstructured":"Byrne C, Ursin G, Martin CF, Peck JD, Cole EB, Zeng D, et al. Mammographic density change with estrogen and progestin therapy and breast cancer risk. J Natl Cancer Inst. 2017;109(9):djx001.","DOI":"10.1093\/jnci\/djx001"},{"key":"1425_CR22","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1023\/A:1008926607428","volume":"11","author":"CM Vachon","year":"2000","unstructured":"Vachon CM, Kuni CC, Anderson K, Anderson VE, Sellers TA. Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States). Cancer Causes Control. 2000;11:653\u201362 [cited 2020 Nov 18] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/10977110\/.","journal-title":"Cancer Causes Control"},{"key":"1425_CR23","doi-asserted-by":"crossref","unstructured":"Rutter CM, Mandelson MT, Laya MB, Taplin S, Seger. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. J Am Med Assoc; 2001;285:171\u20136. [cited 2020 Dec 6] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/11176809\/","DOI":"10.1001\/jama.285.2.171"},{"issue":"3","key":"1425_CR24","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/ijc.20710","volume":"114","author":"A Fournier","year":"2005","unstructured":"Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005;114(3):448\u201354. https:\/\/doi.org\/10.1002\/ijc.20710.","journal-title":"Int J Cancer"},{"issue":"6","key":"1425_CR25","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1037\/cou0000242","volume":"64","author":"MJ Valente","year":"2017","unstructured":"Valente MJ, Pelham WE, Smyth H, MacKinnon DP. Confounding in statistical mediation analysis: what it is and how to address it. J Couns Psychol. 2017;64(6):659\u201371. https:\/\/doi.org\/10.1037\/cou0000242.","journal-title":"J Couns Psychol"},{"key":"1425_CR26","doi-asserted-by":"crossref","unstructured":"Szklo M. Population-based cohort studies. Epidemiol. Rev. John Hopkins University School of Hygiene and Public Health; 1998 [cited 2020 Dec 9]. p. 81\u201390. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/9762511\/","DOI":"10.1093\/oxfordjournals.epirev.a017974"},{"key":"1425_CR27","first-page":"15","volume":"36","author":"C Flamant","year":"2005","unstructured":"Flamant C, Gauthier E, Clavel-Chapelon F. Profil des femmes ne respectant pas les recommandationssur le d\u00e9pistage du cancer du sein par mammographie. R\u00e9sultats de la cohorte E3N. Rev Med Ass Mal. 2005;36:15\u201322.","journal-title":"Rev Med Ass Mal"},{"issue":"25","key":"1425_CR28","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1056\/NEJM199706193362501","volume":"336","author":"F Grodstein","year":"1997","unstructured":"Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, et al. Postmenopausal hormone therapy and mortality. N Engl J Med. 1997;336(25):1769\u201375. https:\/\/doi.org\/10.1056\/NEJM199706193362501.","journal-title":"N Engl J Med"},{"issue":"12","key":"1425_CR29","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.7326\/0003-4819-117-12-1016","volume":"117","author":"D Grady","year":"1992","unstructured":"Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117(12):1016\u201337. https:\/\/doi.org\/10.7326\/0003-4819-117-12-1016.","journal-title":"Ann Intern Med"},{"key":"1425_CR30","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.atherosclerosis.2016.10.005","volume":"254","author":"RA Lobo","year":"2016","unstructured":"Lobo RA, Pickar JH, Stevenson JC, Mack WJ, Hodis HN. Back to the future: hormone replacement therapy as part of a prevention strategy for women at the onset of menopause. Atherosclerosis. 2016;254:282\u201390. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.10.005.","journal-title":"Atherosclerosis"},{"key":"1425_CR31","doi-asserted-by":"crossref","unstructured":"Grady D, Cummings S, Petitti D, Rubin S, Audet A, Sox H, et al. Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med. 1992;117(12):1038\u201341.","DOI":"10.7326\/0003-4819-117-12-1016"},{"key":"1425_CR32","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"JE Rossouw","year":"2002","unstructured":"Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial. JAMA. 2002;288:321\u201333.","journal-title":"JAMA"},{"key":"1425_CR33","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.brainres.2010.10.076","volume":"1379","author":"HN Hodis","year":"2011","unstructured":"Hodis HN, Mack WJ. A \u201cwindow of opportunity:\u201d the reduction of coronary heart disease and total mortality with menopausal therapies is age- and time-dependent. Brain Res. 2011;1379:244\u201352. https:\/\/doi.org\/10.1016\/j.brainres.2010.10.076.","journal-title":"Brain Res"},{"key":"1425_CR34","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2013.278040","volume":"310","author":"JE Manson","year":"2013","unstructured":"Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women\u2019s Health Initiative randomized trials. JAMA. 2013;310:1353\u201368.","journal-title":"JAMA"},{"key":"1425_CR35","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1525-1497.2006.00389.x","volume":"21","author":"SR Salpeter","year":"2006","unstructured":"Salpeter SR, Walsh JME, Greyber E, Salpeter EE. Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med. 2006;21:363\u20136.","journal-title":"J Gen Intern Med"},{"issue":"7","key":"1425_CR36","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/j.1525-1497.2004.30281.x","volume":"19","author":"SR Salpeter","year":"2004","unstructured":"Salpeter SR, Walsh JME, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med. 2004;19(7):791\u2013804. https:\/\/doi.org\/10.1111\/j.1525-1497.2004.30281.x.","journal-title":"J Gen Intern Med"},{"key":"1425_CR37","doi-asserted-by":"crossref","unstructured":"Boardman HMP, Hartley L, Eisinga A, Main C, Roque i Figuls M, Bonfill Cosp X, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015;(3):CD002229.","DOI":"10.1002\/14651858.CD002229.pub4"},{"key":"1425_CR38","doi-asserted-by":"crossref","unstructured":"Vogel L. Hormone therapy study restokes debate over breast cancer risk. C Can Med Assoc J = J l\u2019Association medicale Can. 2019;191:E1088\u20139.","DOI":"10.1503\/cmaj.1095815"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-021-01425-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-021-01425-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-021-01425-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T09:05:27Z","timestamp":1618650327000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-021-01425-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,17]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1425"],"URL":"https:\/\/doi.org\/10.1186\/s13058-021-01425-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-57670\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-57670\/v1","asserted-by":"object"}]},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,17]]},"assertion":[{"value":"3 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants signed informed consent in compliance with the rules of the French National Commission for Computed Data and Individual Freedom (Commission Nationale de l\u2019Informatique et des Libert\u00e9s), from which we obtained approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}